Effect of Use of Calcium Hydroxide and Metformin Intracanal Medicament After NSRCT

NCT06766201 on ClinicalTrials.gov Phase 2/3 Postgraduate Institute of Dental Sciences Rohtak (academic or other) Started 2023-08-01 Completed

Riskier than 5% of active trials

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2025-01-01, after 2023-08-01 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Accepts healthy volunteers: Yes (lowers risk) · Who can join
Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientsscoreintravenouscalciumpresence
Phrases that lowered it: effect ofhealthythe effecttrialevaluate the
Trials the sponsor started in the prior 2 years: 41 (lowers risk) · Sponsor's track record
Responsible party: principal investigator (lowers risk) · Design
Drug's FAERS reports with a death: 8.2% (lowers risk) · Drug's FDA history
Design: parallel (raises risk) · Design
Sponsor type: academic or other (raises risk) · Sponsor's track record
Has a data monitoring committee: Yes (raises risk) · Design
Drug's FAERS reports marked serious: 67.3% (lowers risk) · Drug's FDA history
Minimum age: 18 (raises risk) · Who can join
Disease area, cancer: No (lowers risk) · Disease area
Primary purpose: treatment (raises risk) · Design
Drug's FAERS reports before start: 397909 (lowers risk) · Drug's FDA history
Phase: 2/3 (raises risk) · Design
Blinding: double (raises risk) · Design
Sponsor's past trials: 45 (lowers risk) · Sponsor's track record
Maximum age: 55 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 2/3 (typical: 2)
Number of arms: 2
Allocation: randomized
Design: parallel
Primary purpose: treatment
Blinding: double (typical: none)
Has a data monitoring committee: Yes (typical: 56% yes)
Responsible party: principal investigator (typical: sponsor)
Collaborators: 0
Keywords listed: 1

Who can join

Minimum age: 18
Maximum age: 55 (typical: 71)
Sex: all
Accepts healthy volunteers: Yes (typical: 9% yes)

Sponsor's track record

Sponsor type: academic or other
Sponsor's past trials: 45 (typical: 32)
Sponsor's past termination rate: 0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 41 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 397909 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 29038 (typical: 412.5)
Drug's FAERS reports marked serious: 67.3% (typical: 85.6%)
Drug's FAERS reports with a death: 8.2% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: metformin

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Single Versus Multiple Visits Endodontic Treatment NCT02947763 · started 2016 · scored riskier than 8% of active trials completed
Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing NCT06342830 · started 2024 · scored riskier than 6% of active trials completed
Regenerative Endodontic Therapy (RET) for the Management of Immature Non-vital Permanent Teeth in Children NCT03327844 · started 2017 · scored riskier than 9% of active trials completed
Molecular Analysis of Intracanal Microbes After Chemomechanical Procedure and Root Canal Medication: A Randomized Controlled Trial NCT06291623 · started 2022 · scored riskier than 5% of active trials completed
Role of Propolis Paste in Preventing Pain After Root Canal Treatment. NCT03723980 · started 2017 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.